Literature DB >> 12410198

Grading of hemorrhage in children with idiopathic thrombocytopenic purpura.

George R Buchanan1, Leah Adix.   

Abstract

OBJECTIVE: To develop an instrument to allow semiquantitative assessment of hemorrhage in children with idiopathic thrombocytopenic purpura (ITP). STUDY
DESIGN: Bleeding severity was graded on a scale of 0 to 4 in 4 different sites (overall, oral, epistaxis, and skin) on the basis of history during the previous 24 hours and physical examination.
RESULTS: Children with ITP (n = 54) were assessed on 109 different occasions by multiple observers, including 81 measurements by one of the authors. Grade of bleeding correlated inversely with platelet count. Grade 3 or 4 hemorrhage was infrequently encountered except involving the skin, where assessment was difficult. Grade 4 mucosal or internal hemorrhage was noted in 7 patients; none had life-threatening or fatal bleeding. Interrater agreement in grading of overall and mouth bleeding and epistaxis was acceptable.
CONCLUSIONS: We conclude that scoring of hemorrhage is possible in children with ITP and that the grade of hemorrhage may represent a clinically meaningful end point in future studies.

Entities:  

Mesh:

Year:  2002        PMID: 12410198     DOI: 10.1067/mpd.2002.128547

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  45 in total

1.  Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan.

Authors:  Takaaki Hato; Naoki Shimada; Yoshiyuki Kurata; Masataka Kuwana; Kingo Fujimura; Hirokazu Kashiwagi; Toshiro Takafuta; Mitsuru Murata; Yoshiaki Tomiyama
Journal:  Blood Adv       Date:  2020-04-28

2.  Does treatment of newly diagnosed idiopathic thrombocytopenic purpura reduce morbidity?

Authors:  Iris Treutiger; Jukka Rajantie; Bernward Zeller; Jan-Inge Henter; Göran Elinder; Steen Rosthøj
Journal:  Arch Dis Child       Date:  2007-04-25       Impact factor: 3.791

3.  Health-related quality of life in children with newly diagnosed immune thrombocytopenia.

Authors:  Katja M J Heitink-Pollé; Lotte Haverman; Kim V Annink; Sarah J Schep; Masja de Haas; Marrie C A Bruin
Journal:  Haematologica       Date:  2014-06-20       Impact factor: 9.941

4.  Legionellosis must be kept in mind in case of pneumonia with lung abscesses in children receiving therapeutic steroids.

Authors:  S Heine; A Fuchs; L von Müller; T Krenn; S Nemat; N Graf; A Simon
Journal:  Infection       Date:  2011-06-29       Impact factor: 3.553

Review 5.  Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?

Authors:  J E Vaughn; F Anwer; H J Deeg
Journal:  Vox Sang       Date:  2015-07-14       Impact factor: 2.144

6.  Thromboelastographic changes after gonadectomy in retired racing greyhounds.

Authors:  P Vilar Saavedra; N Stingle; C Iazbik; L Marín; M A McLoughlin; Y Xie; G Couto
Journal:  Vet Rec       Date:  2011-07-01       Impact factor: 2.695

7.  IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP.

Authors:  Manuel Carcao; Mariana Silva; Michele David; Robert J Klaassen; MacGregor Steele; Victoria Price; Cindy Wakefield; Lussia Kim; Derek Stephens; Victor S Blanchette
Journal:  Blood Adv       Date:  2020-04-14

Review 8.  Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.

Authors:  C Neunert; N Noroozi; G Norman; G R Buchanan; J Goy; I Nazi; J G Kelton; D M Arnold
Journal:  J Thromb Haemost       Date:  2015-01-14       Impact factor: 5.824

9.  Rotavirus-associated immune thrombocytopenic purpura in children: A retrospective study.

Authors:  Qi Ai; Jing Yin; Sen Chen; Lijin Qiao; Na Luo
Journal:  Exp Ther Med       Date:  2016-08-09       Impact factor: 2.447

10.  Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.

Authors:  Hannah Tamary; Jelena Roganovic; Meera Chitlur; Diane J Nugent
Journal:  Ann Hematol       Date:  2010-04-01       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.